211 related articles for article (PubMed ID: 21646492)
1. Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators.
Morero NR; Monti MR; Argaraña CE
Antimicrob Agents Chemother; 2011 Aug; 55(8):3668-76. PubMed ID: 21646492
[TBL] [Abstract][Full Text] [Related]
2. Real-Time Monitoring of
Zaborskyte G; Andersen JB; Kragh KN; Ciofu O
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993856
[TBL] [Abstract][Full Text] [Related]
3. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump.
Jeannot K; Elsen S; Köhler T; Attree I; van Delden C; Plésiat P
Antimicrob Agents Chemother; 2008 Jul; 52(7):2455-62. PubMed ID: 18474583
[TBL] [Abstract][Full Text] [Related]
4. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance.
Bruchmann S; Dötsch A; Nouri B; Chaberny IF; Häussler S
Antimicrob Agents Chemother; 2013 Mar; 57(3):1361-8. PubMed ID: 23274661
[TBL] [Abstract][Full Text] [Related]
5. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.
Dean CR; Visalli MA; Projan SJ; Sum PE; Bradford PA
Antimicrob Agents Chemother; 2003 Mar; 47(3):972-8. PubMed ID: 12604529
[TBL] [Abstract][Full Text] [Related]
6. The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran.
Nouri R; Ahangarzadeh Rezaee M; Hasani A; Aghazadeh M; Asgharzadeh M
Braz J Microbiol; 2016; 47(4):925-930. PubMed ID: 27522930
[TBL] [Abstract][Full Text] [Related]
7. gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon.
Salma R; Dabboussi F; Kassaa I; Khudary R; Hamze M
J Infect Chemother; 2013 Feb; 19(1):77-81. PubMed ID: 22821356
[TBL] [Abstract][Full Text] [Related]
8. Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin.
Llanes C; Köhler T; Patry I; Dehecq B; van Delden C; Plésiat P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5676-84. PubMed ID: 21911574
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms decreasing in vitro susceptibility to the LpxC inhibitor CHIR-090 in the gram-negative pathogen Pseudomonas aeruginosa.
Caughlan RE; Jones AK; Delucia AM; Woods AL; Xie L; Ma B; Barnes SW; Walker JR; Sprague ER; Yang X; Dean CR
Antimicrob Agents Chemother; 2012 Jan; 56(1):17-27. PubMed ID: 22024823
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Compensation of Fitness Costs Is a General Outcome for Antibiotic-Resistant
Olivares Pacheco J; Alvarez-Ortega C; Alcalde Rico M; Martínez JL
mBio; 2017 Jul; 8(4):. PubMed ID: 28743808
[TBL] [Abstract][Full Text] [Related]
11. High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation.
Nakajima A; Sugimoto Y; Yoneyama H; Nakae T
Microbiol Immunol; 2002; 46(6):391-5. PubMed ID: 12153116
[TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa deficient in 8-oxodeoxyguanine repair system shows a high frequency of resistance to ciprofloxacin.
Morero NR; Argaraña CE
FEMS Microbiol Lett; 2009 Jan; 290(2):217-26. PubMed ID: 19025574
[TBL] [Abstract][Full Text] [Related]
13. Construction of a series of mutants lacking all of the four major mex operons for multidrug efflux pumps or possessing each one of the operons from Pseudomonas aeruginosa PAO1: MexCD-OprJ is an inducible pump.
Morita Y; Komori Y; Mima T; Kuroda T; Mizushima T; Tsuchiya T
FEMS Microbiol Lett; 2001 Aug; 202(1):139-43. PubMed ID: 11506922
[TBL] [Abstract][Full Text] [Related]
14. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
Lei YC; Wang HB; Sun ZY; Shen ZY
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
[TBL] [Abstract][Full Text] [Related]
15. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
Lee JK; Lee YS; Park YK; Kim BS
Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ.
Chuanchuen R; Beinlich K; Hoang TT; Becher A; Karkhoff-Schweizer RR; Schweizer HP
Antimicrob Agents Chemother; 2001 Feb; 45(2):428-32. PubMed ID: 11158736
[TBL] [Abstract][Full Text] [Related]
17. Lack of the Major Multifunctional Catalase KatA in Pseudomonas aeruginosa Accelerates Evolution of Antibiotic Resistance in Ciprofloxacin-Treated Biofilms.
Ahmed MN; Porse A; Abdelsamad A; Sommer M; Høiby N; Ciofu O
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31307984
[TBL] [Abstract][Full Text] [Related]
18. Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa.
Zhao L; Wang S; Li X; He X; Jian L
Antimicrob Resist Infect Control; 2020 Aug; 9(1):124. PubMed ID: 32758289
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa.
Pan YP; Xu YH; Wang ZX; Fang YP; Shen JL
Arch Microbiol; 2016 Aug; 198(6):565-71. PubMed ID: 27060003
[TBL] [Abstract][Full Text] [Related]
20. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P
J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
